Metabolomics reveals signature of mitochondrial dysfunction in diabetic kidney disease.

Diabetic kidney disease is the leading cause of ESRD, but few biomarkers of diabetic kidney disease are available. This study used gas chromatography-mass spectrometry to quantify 94 urine metabolites in screening and validation cohorts of patients with diabetes mellitus (DM) and CKD(DM+CKD), in patients with DM without CKD (DM-CKD), and in healthy controls. Compared with levels in healthy controls, 13 metabolites were significantly reduced in the DM+CKD cohorts (P≤0.001), and 12 of the 13 remained significant when compared with the DM-CKD cohort. Many of the differentially expressed metabolites were water-soluble organic anions. Notably, organic anion transporter-1 (OAT1) knockout mice expressed a similar pattern of reduced levels of urinary organic acids, and human kidney tissue from patients with diabetic nephropathy demonstrated lower gene expression of OAT1 and OAT3. Analysis of bioinformatics data indicated that 12 of the 13 differentially expressed metabolites are linked to mitochondrial metabolism and suggested global suppression of mitochondrial activity in diabetic kidney disease. Supporting this analysis, human diabetic kidney sections expressed less mitochondrial protein, urine exosomes from patients with diabetes and CKD had less mitochondrial DNA, and kidney tissues from patients with diabetic kidney disease had lower gene expression of PGC1α (a master regulator of mitochondrial biogenesis). We conclude that urine metabolomics is a reliable source for biomarkers of diabetic complications, and our data suggest that renal organic ion transport and mitochondrial function are dysregulated in diabetic kidney disease.

[1]  B. Viollet,et al.  AMPK dysregulation promotes diabetes-related reduction of superoxide and mitochondrial function. , 2013, The Journal of clinical investigation.

[2]  Loki Natarajan,et al.  Statistical tests for the intersection of independent lists of genes: Sensitivity, FDR, and type I error control , 2012, 1206.6636.

[3]  Loki Natarajan,et al.  Exact statistical tests for the intersection of independent lists of genes. , 2012, The annals of applied statistics.

[4]  W. R. Wikoff,et al.  Untargeted metabolomics identifies enterobiome metabolites and putative uremic toxins as substrates of organic anion transporter 1 (Oat1). , 2011, Journal of proteome research.

[5]  M. Donohue,et al.  Pirfenidone for diabetic nephropathy. , 2011, Journal of the American Society of Nephrology : JASN.

[6]  V. Mootha,et al.  Metabolite profiles and the risk of developing diabetes , 2011, Nature Medicine.

[7]  J. Skupień,et al.  Risk for ESRD in type 1 diabetes remains high despite renoprotection. , 2011, Journal of the American Society of Nephrology : JASN.

[8]  T. Hankemeier,et al.  Discovery of early-stage biomarkers for diabetic kidney disease using ms-based metabolomics (FinnDiane study) , 2011, Metabolomics.

[9]  A. Dnyanmote,et al.  Remote Communication through Solute Carriers and ATP Binding Cassette Drug Transporter Pathways: An Update on the Remote Sensing and Signaling Hypothesis , 2011, Molecular Pharmacology.

[10]  J. Zierath,et al.  Non-CpG methylation of the PGC-1alpha promoter through DNMT3B controls mitochondrial density. , 2009, Cell metabolism.

[11]  S. Nigam,et al.  Toward a Systems Level Understanding of Organic Anion and Other Multispecific Drug Transporters: A Remote Sensing and Signaling Hypothesis , 2009, Molecular Pharmacology.

[12]  Merlin C. Thomas,et al.  The Presence and Severity of Chronic Kidney Disease Predicts All-Cause Mortality in Type 1 Diabetes , 2009, Diabetes.

[13]  Svati H Shah,et al.  A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. , 2009, Cell metabolism.

[14]  G. Illei,et al.  Urinary exosomal transcription factors, a new class of biomarkers for renal disease. , 2008, Kidney international.

[15]  P. Swaan,et al.  Structural Variation Governs Substrate Specificity for Organic Anion Transporter (OAT) Homologs , 2007, Journal of Biological Chemistry.

[16]  S. Nigam,et al.  Drug and toxicant handling by the OAT organic anion transporters in the kidney and other tissues , 2007, Nature Clinical Practice Nephrology.

[17]  B. Spiegelman.  Transcriptional control of mitochondrial energy metabolism through the PGC1 coactivators. , 2007, Novartis Foundation symposium.

[18]  Felix Eichinger,et al.  Modular Activation of Nuclear Factor-κB Transcriptional Programs in Human Diabetic Nephropathy , 2006, Diabetes.

[19]  V. Vallon,et al.  Decreased Renal Organic Anion Secretion and Plasma Accumulation of Endogenous Organic Anions in OAT1 Knock-out Mice* , 2006, Journal of Biological Chemistry.

[20]  R. Spielman,et al.  Assessment of 115 candidate genes for diabetic nephropathy by transmission/disequilibrium test. , 2005, Diabetes.

[21]  K. Sharma,et al.  Two‐dimensional fluorescence difference gel electrophoresis analysis of the urine proteome in human diabetic nephropathy , 2005, Proteomics.

[22]  W. Nyhan,et al.  Methylcitrate in maternal urine during a pregnancy with a fetus affected with propionic acidaemia , 1989, Journal of Inherited Metabolic Disease.

[23]  H. Takanaga,et al.  Mouse Reduced in Osteosclerosis Transporter Functions as an Organic Anion Transporter 3 and Is Localized at Abluminal Membrane of Blood-Brain Barrier , 2004, Journal of Pharmacology and Experimental Therapeutics.

[24]  D. Liang,et al.  Molecular profiling of diabetic mouse kidney reveals novel genes linked to glomerular disease. , 2004, Diabetes.

[25]  C. Cohen,et al.  Quantitative gene expression analysis in renal biopsies: a novel protocol for a high-throughput multicenter application. , 2002, Kidney international.

[26]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[27]  W. Nyhan,et al.  Quantitative analysis for organic acids in biological samples: batch isolation followed by gas chromatographic-mass spectrometric analysis. , 1989, Clinical chemistry.

[28]  G. Oster,et al.  Characteristics and healthcare costs of patients with fibromyalgia syndrome , 2007, International journal of clinical practice.

[29]  W. Nyhan,et al.  Detailed comparison of the urinary excretion of purines in a patient with the Lesch-Nyhan syndrome and a control subject. , 1970, Biochemical medicine.

[30]  W L Nyhan,et al.  A new disorder of purine metabolism with behavioral manifestations. , 1969, The Journal of pediatrics.